The Abyssomicin C family as in vitro inhibitors of Mycobacterium tuberculosis

Joel S. Freundlich, Mallikarjun Lalgondar, Jun Rong Wei, Stephanie Swanson, Erik J. Sorensen, Eric J. Rubin, James C. Sacchettini

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


The antimycobacterial efficacy of the abyssomicin C family of natural products, in addition to a key synthetic intermediate, has been investigated given their reported inhibition of Bacillus subtilis p-aminobenzoate biosynthesis. The naturally occurring (-)-abyssomicin C and its atropisomer were found to exhibit low micromolar growth inhibition against the relatively fast-growing and non-virulent Mycobacterium smegmatis and the vaccine strain Mycobacterium bovis BCG, while their antipodes were slightly less active. (-)-Abyssomicin C and its atropisomer were particularly efficacious against Mycobacterium tuberculosis H37Rv, exhibiting MIC values of 3.6 and 7.2 μM, respectively. More specifically, (-)-abyssomicin C was bactericidal. This complex natural product and its analogs, thus, hold promise as chemical tools in the study of M. tuberculosis metabolism.

Original languageEnglish (US)
Pages (from-to)298-300
Number of pages3
Issue number5
StatePublished - Sep 2010

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases
  • Microbiology
  • Immunology


  • Abyssomicin
  • Mycobacterium tuberculosis
  • p-Aminobenzoate metabolism


Dive into the research topics of 'The Abyssomicin C family as in vitro inhibitors of Mycobacterium tuberculosis'. Together they form a unique fingerprint.

Cite this